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Fibrinogen is a plasma glycoprotein synthesised 
by the liver which plays a critical role in haemostasis 
by acting as an endogenous substrate for fibrin 
formation and by inducing clot formation and platelet 
aggregation1. A deficiency in fibrinogen may be 
inherited or acquired, the latter condition developing 
predominantly in association with trauma-related 
or peri-operative major bleeding2,3. Fibrinogen 
supplementation can be achieved using fresh-frozen 
plasma, cryoprecipitate or plasma-derived, virally-
inactivated, fibrinogen concentrate4-8.
Although a number of studies have reported the use of 
fibrinogen concentrate for the treatment and prevention 
of acquired bleeding, its beneficial effect is still debated, 
mainly due to the low quality of the published clinical 
evidence9. For instance, a Cochrane review published 
in 2013 by Wikkelsø and Colleagues10, which evaluated 
fibrinogen concentrate in 248 bleeding patients enrolled 
in six randomised controlled trials, concluded that, 
besides an apparent effect on the reduction of transfusion 
requirements, the heterogeneity and the high risk of bias 
of these studies prevented a proper evaluation of any 
beneficial effect of fibrinogen concentrate. 
The topic of the beneficial effects of fibrinogen 
concentrate in surgical patients was recently reviewed 
by another meta-analysis published by Fominskiy and 
Colleagues11. This review paper pooled 14 original 
studies12-24, all with a prospective, randomised controlled 
design. The end-points focused on in the meta-analysis 
were all-cause mortality, volume of bleeding, and red 
blood cell units transfused. Data regarding the first 
end-point, which were drawn from ten studies, showed 
a consistently lower cumulative rate of fatal events in 
the pooled arm of fibrinogen-treated patients than in the 
placebo-treated control arm, as evaluated by the risk 
ratio (0.26) with a 95% confidence interval (95% CI) of 
0.09 to 0.78 (p=0.02). The authors, however, included 
data on all-cause mortality obtained in a multicentre 
study conducted by Rahe-Meyer (oral presentation 
during the 2015 Annual Congress of the European 
Society of Anaesthesiology, Berlin, May 30-June 2, 
2015), still unpublished on the date of submission of the 
meta-analysis. These data were subsequently published 
by the same author, albeit with minor changes (a total 
of 152 patients enrolled instead of 142)25.
The use of fibrinogen concentrate was also associated 
with a significantly less bleeding (nine studies included) 
and a lower number of red blood cell units transfused 
(nine studies included), but the mean differences of 
these quantitative indices were modest (−127 mL 
and −0.93 units, respectively). Differences in other 
indices were of borderline statistical significance, but 
were not significant when Bonferroni's correction was 
applied (the number of patients receiving red blood cell 
transfusions and the number of patients receiving any 
blood components). Moreover, the number of surgical 
revisions for bleeding, the rate of thrombotic events, 
and the incidence of myocardial infarction were not 
statistically significantly different between the patients 
who received fibrinogen concentrate and those who 
did not.
Considering this meta-analysis11 in greater detail, 
a number of criticisms can be levelled against it. The 
first is that it seems improper to put together studies 
dealing with different clinical diseases, with patients 
being submitted to a very wide variety of surgical 
procedures. Most patients had coronary artery disease 
and were submitted to cardiopulmonary shunting 
with anticoagulant treatment. Two studies concerned 
paediatric patients with severe congenital heart 
disease12,14, one study collected liver transplant recipients 
(in whom the basal severe liver failure could have caused 
deficient synthesis of clotting factors)21, one study was 
on women with severe post-partum haemorrhages24, and 
one study was on patients undergoing total cystectomy13. 
In addition, two studies used active comparators, in 
one instance platelet transfusion23, and in the other 
cryoprecipitate14. 
Another concern is the use of "all-cause mortality 
at the longest follow-up available" as a proper index 
of efficacy in the context of surgery. Fibrinogen 
is a clotting factor, and in a surgical context a 
pro-haemorrhagic effect in the control arm is expected 
to happen early. So, early deaths (in the first 7-10 days 
after surgery) would have been a more suitable index 
than later mortality, which seems due mostly to the 
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baseline clinical condition. Unfortunately, only the 
study by Rahe-Meyer and Colleagues published in 2016 
distinguished early deaths from later ones25, whereas 
most studies neither indicated the time of deaths, nor 
mentioned the time limits of surveillance for untoward 
events. Interestingly, while this latter study reported 
one death in the fibrinogen arm and five deaths in the 
control arm, the early deaths ("between 1 and 10 days 
after study medication") as well as the treatment-related 
adverse events were balanced (1:1 and 4:4, respectively). 
Notably, most of the deaths in the review11 were reported 
in the two subsequent studies published by Rahe-Meyer 
and Colleagues in 2013 and 201619,25. The all-cause 
mortality appeared significant. However, this large 
effect size (reducing the risk by almost three-quarters 
in fibrinogen-treated patients) was hardly justified 
by the modest reduction in the fibrinogen arm of the 
other two quantitative end-points reported in detail: 
post-operative bleeding (mean difference, −127 mL), 
and number of transfused red blood cell units (mean 
difference, −0.93 units). Differences in the latter end-
points were statistically significant, but quantitatively 
modest. A likely explanation for this incongruity 
could be the comparative index chosen for mortality 
cumulative incidence, relative risk. First, this choice of 
index excludes all eventless studies from the quantitative 
evaluation (6 studies out 10)26. Moreover, since the 
relative risk is a ratio between incidences, it masks the 
substantive rareness of deaths. Indeed, fatal events were 
uncommon, with 19 deaths among 872 patients (about 
2.2%). We would have preferred another comparative 
index, the risk difference, which does not suffer from 
these drawbacks. In addition, the risk difference enables 
calculation of an important pharmaco-economic index, 
the number-needed-to-treat. We calculated the pooled 
inverse-variance risk difference on the same ten papers 
considered in the meta-analysis. Using the method of 
Mantel-Haenszel the index was significant, with a mean 
−2.5% (95% CI: −4.7% to −0.3%, p=0.024). However, 
with the inverse variance method, a lower mean was 
found, 0.07% (95% CI: −2% to 0.7%, p: not significant). 
Clearly, these estimates suffer of a degree of instability. 
Indeed, all classical meta-analytical methods are less 
than satisfactory with rare events27,28. A remedy could 
consist in logistic or Poisson regression for hierarchical 
data, taking into account the studies as grouping 
variable29,30. With the former method, the estimated 
mean risk difference was −1.4% (95% CI: −5.0% to 
−0.4%, p=0.016), and the results were very similar with 
the latter. The estimates were statistically significant, 
but the effect sizes were low. Another method that 
appears suitable for determining risk difference when 
events are rare was recently developed by Tian and 
Colleagues31. This method is based on the combination 
of the study-level risk difference distributions32,33. Using 
this procedure, the mean risk difference was estimated 
as −1.6% (95% CI: −5.8% to 0.1%, p=0.086) and the 
corresponding number-needed-to-treat (i.e., the number 
of patients who need to be treated with fibrinogen in 
order to save one life) was 61.
In conclusion, for a series of methodological aspects, 
the evidence collected by the above-cited meta-analysis11 
seems weak and insufficient as a basis for therapeutic or 
prophylactic guidelines, as highlighted in the previously 
published Cochrane meta-analysis10.
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